Pulmonx (LUNG) Expected to Announce Earnings on Wednesday

Pulmonx (NASDAQ:LUNG) will likely be releasing its Q3 2025 results before the market opens on Wednesday, October 29th. Analysts expect the company to announce earnings of ($0.40) per share and revenue of $20.7840 million for the quarter. Pulmonx has set its FY 2025 guidance at EPS.Parties may review the information on the company’s upcoming Q3 2025 earningreport for the latest details on the call scheduled for Wednesday, October 29, 2025 at 4:30 PM ET.

Pulmonx (NASDAQ:LUNG) last issued its quarterly earnings results on Wednesday, July 30th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.40) by $0.02. The firm had revenue of $23.86 million for the quarter, compared to analyst estimates of $23.46 million. Pulmonx had a negative return on equity of 69.76% and a negative net margin of 62.88%. On average, analysts expect Pulmonx to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Pulmonx Stock Performance

Shares of LUNG stock opened at $1.61 on Wednesday. The firm has a 50 day moving average of $1.67 and a 200-day moving average of $2.79. The company has a market cap of $65.61 million, a price-to-earnings ratio of -1.13 and a beta of 0.42. The company has a quick ratio of 4.63, a current ratio of 5.35 and a debt-to-equity ratio of 0.54. Pulmonx has a 52 week low of $1.47 and a 52 week high of $9.37.

Institutional Investors Weigh In On Pulmonx

Institutional investors have recently bought and sold shares of the stock. XTX Topco Ltd bought a new position in Pulmonx during the 2nd quarter valued at $149,000. Jane Street Group LLC raised its holdings in shares of Pulmonx by 3,328.7% in the second quarter. Jane Street Group LLC now owns 88,631 shares of the company’s stock valued at $230,000 after purchasing an additional 86,046 shares during the last quarter. Norges Bank purchased a new stake in shares of Pulmonx in the second quarter valued at about $392,000. Finally, Bank of America Corp DE boosted its holdings in Pulmonx by 556.6% during the second quarter. Bank of America Corp DE now owns 481,268 shares of the company’s stock worth $1,246,000 after purchasing an additional 407,971 shares during the last quarter. Institutional investors own 91.04% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the stock. Piper Sandler lowered shares of Pulmonx from an “overweight” rating to a “neutral” rating and dropped their price objective for the company from $9.00 to $2.50 in a report on Thursday, July 31st. Wells Fargo & Company cut their price target on Pulmonx from $6.00 to $3.00 and set an “equal weight” rating on the stock in a report on Friday, August 1st. Lake Street Capital decreased their price objective on Pulmonx from $12.00 to $8.00 and set a “buy” rating for the company in a report on Thursday, July 31st. Wall Street Zen cut Pulmonx from a “hold” rating to a “sell” rating in a report on Friday, October 3rd. Finally, D. Boral Capital restated a “buy” rating and set a $16.00 price target on shares of Pulmonx in a research note on Monday, September 8th. Five analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $7.66.

Pulmonx Company Profile

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.